Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China

PLoS One. 2017 Jan 24;12(1):e0168865. doi: 10.1371/journal.pone.0168865. eCollection 2017.

Abstract

Little is known about the impact of drug resistance on recurrence in TB. We conducted a cohort study to measure the impact of multi-drug resistance (MDR) on TB recurrence over nine years in Henan Province China. We reviewed medical records and conducted field interviews of 100 MDR and 150 non-MDR TB patients who were treated between 2001 and 2002. We compared long-term recurrence rates, risk factors, and outcomes in 2010 for 234 individuals who could be followed up. About one third (29.5%, 69/234) suffered recurrence after completion of treatment. The overall recurrence rate was 35/1,000 patient-years (PY), with a much higher rate (65/1,000 PY) among MDR-TB patients. MDR (HR: 2.75; CI: 1.58-4.79) and patient annual household income less than 10,000 Yuan (HR: 2.05; CI 1.11-3.80) were associated with recurrence. The mean time for recurrence among MDR-TB patients was 5.7 years, compared to 7.2 years among non-MDR-TB patients. Among the recurrence group members, 61.3% died, and 18.8% had failed treatments. We believe that the high TB recurrence rate after 9 years suggests that a high cure rate cannot accurately predict long-term outcome. We recommend that TB surveillance and control should be strengthened with a focus on MDR-TB and directly observed treatment, to reduce TB recurrence and transmission of MDR-TB.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Agricultural Workers' Diseases / drug therapy
  • Agricultural Workers' Diseases / economics
  • Agricultural Workers' Diseases / epidemiology
  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • China / epidemiology
  • Comorbidity
  • Drug Resistance, Multiple, Bacterial*
  • Female
  • Follow-Up Studies
  • Humans
  • Income
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects*
  • Recurrence
  • Risk Factors
  • Sampling Studies
  • Socioeconomic Factors
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / economics
  • Tuberculosis, Multidrug-Resistant / epidemiology*
  • Young Adult

Substances

  • Antitubercular Agents

Grants and funding

The Funding for the study was partially provided by the Centre for Epidemiology and Population Health, Australian National University, as the PhD study project for Yanni Sun, a PhD candidate at the Centre. Yanni Sun also paid in part for the study as the internal budget was insufficient. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.